ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF) (CONSORT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00249834
Recruitment Status : Completed
First Posted : November 7, 2005
Results First Posted : March 30, 2018
Last Update Posted : March 30, 2018
Sponsor:
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany

Brief Summary:
Clinical validation of the assisted reproductive technology (ART) treatment guidelines, which determine the optimal dose of recombinant human follicle stimulating hormone (r-hFSH) based on subject baseline characteristics/predictors of ovarian response.

Condition or disease Intervention/treatment Phase
Infertility Drug: Gonal-f Drug: Recombinant human chorionic gonadotrophin (r-hCG) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIIB/IV, Open Label Study to Assess the Efficacy and Safety of a Pre-defined, Fixed Dose of Gonal-f® (Filled-by-Mass in a Prefilled Pen) Based on Subject Baseline Characteristics, for Ovarian Stimulation in Subjects Undergoing in Vitro Fertilization (IVF)
Actual Study Start Date : September 22, 2004
Actual Primary Completion Date : January 16, 2006
Actual Study Completion Date : January 16, 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: Gonal-f 112.5 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 37.5 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 75 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 150 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 187.5 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 225 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 262.5 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Experimental: Gonal-f 300 IU Drug: Gonal-f
GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Other Names:
  • follitropin alfa
  • Recombinant Human Follicle Stimulating Hormone (r-hFSH)

Drug: Recombinant human chorionic gonadotrophin (r-hCG)
When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.




Primary Outcome Measures :
  1. Number of Oocytes Retrieved [ Time Frame: Ovum pick up day (34 to 38 hours post r-hCG administration) ]
    Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.


Secondary Outcome Measures :
  1. Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH) [ Time Frame: up to end of stimulation cycle (approximately 31 days) ]
    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  2. Mean Number of Ovarian Stimulation Days [ Time Frame: up to end of stimulation cycle (approximately 31 days) ]
    The mean number of stimulation days were determined based on the treatment administration information collected in the case report form. Ovarian stimulation included time from first r-hFSH injection (stimulation Day) until day on which r-hCG was administered (r-hCG day). As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  3. Percentage of Cycles Cancelled Due to Excessive or Inadequate Response to r-hFSH [ Time Frame: up to end of stimulation cycle (approximately 31 days) ]
    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  4. Number of Subjects Needing Dose Adjustment [ Time Frame: 6 days post r-hFSH treatment ]
    Number of subjects needing increase in dose, decrease in dose or increase and decrease both in dose were reported. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  5. Mean Daily Recombinant Human Follicle Stimulating Hormone (r-hFSH) Dose [ Time Frame: up to end of stimulation cycle (approximately 31 days) ]
    As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  6. Embryo Implantation Rate [ Time Frame: 35-42 days post r-hCG administration ]
    Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.

  7. Overall Pregnancy Rate, Clinical Rate and Multiple Pregnancy Rate [ Time Frame: 35-42 days post r-hCG administration ]
    Overall pregnancy rate was defined as the percentage of subjects with serum beta-hCG levels greater than 10 IU/L. Clinical pregnancy rate was defined as the percentage of subjects with at least 1 ultrasound confirmed gestational sac, with or without foetal heart activity. Multiple pregnancy rate was defined as the percentage of subjects with more than 1 ultrasound confirmed gestational sac in the uterus with fetal heart activity. As per statistical analysis plan, efficacy analysis were performed for only those dose groups (Gonal-f 75 IU, Gonal-f 112.5 IU, Gonal-f 150 IU, Gonal-f 187.5 IU and Gonal-f 225 IU) which included more than 5 subjects.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 34 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Be an infertile subject justifying an in-vitro fertilization/embryo transfer (IVF/ET) treatment.
  • Have a male partner with semen analysis within the past six months prior to study entry considered adequate to proceed with regular insemination or intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If these criteria are not met, the subject can only be entered if donor sperm will be used.
  • Be between her 18th and 35th birthday (35 not included).
  • Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length.
  • Have early follicular phase (Day 2-4) serum levels within the last 3 months prior to study entry of:
  • Follicle stimulating hormone (FSH) greater than or equal to (>=) 12 International units per liter (IU/L), and
  • Oestradiol (E2) within center's local normal laboratory range values.
  • Presence of both ovaries.
  • Have a uterine cavity without abnormalities, which, in the investigator's opinion, could impair embryo implantation or pregnancy evolution as assessed within the last 3 years using ultrasound (US), hysteroscopy (HSC), or hysterosalpingography (HSG).
  • Have a negative cervical papanicolaou (PAP) test within the last 6 months prior to study entry.
  • Have at least one wash-out cycle (defined as >= 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy.
  • Have a negative pregnancy test prior to beginning GnRH agonist therapy.
  • Be willing and able to comply with the protocol for the duration of the study. Have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care.

Exclusion Criteria:

  • Had 2 previous ART cycles with a poor response to gonadotrophin stimulation, defined as less than or equal to (<=) 5 mature follicles and/or <=3 oocytes collected in any previous IVF cycle or hyper response, defined as >=25 oocytes retrieved.
  • Any medical condition, which in the judgement of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Serono's Therapeutic Director.
  • Had previous severe ovarian hyperstimulation syndrome (OHSS).
  • A body mass index (BMI) greater than (>) 30 kilogram per square meter (kg/m^2)
  • Any contraindication to being pregnant and/or carrying a pregnancy to term.
  • Extra-uterine pregnancy within the last 3 months.
  • History of 3 or more miscarriages (early or late miscarriages) due to any cause.
  • Tumours of the hypothalamus and pituitary gland.
  • Ovarian enlargement or cyst of unknown aetiology.
  • Ovarian, uterine or mammary cancer.
  • A clinically significant systemic disease.
  • Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus.
  • Abnormal gynaecological bleeding of undetermined origin.
  • Known allergy or hypersensitivity to human gonadotrophin preparations.
  • Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years.
  • Entered previously into this study or simultaneous participation in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00249834


Locations
France
Medical Information
Paris, France
Sponsors and Collaborators
Merck KGaA, Darmstadt, Germany
Investigators
Study Director: Medical Responsible Merck KGaA, Darmstadt, Germany

Publications of Results:
Other Publications:
Responsible Party: Merck KGaA, Darmstadt, Germany
ClinicalTrials.gov Identifier: NCT00249834     History of Changes
Other Study ID Numbers: 25198
First Posted: November 7, 2005    Key Record Dates
Results First Posted: March 30, 2018
Last Update Posted: March 30, 2018
Last Verified: August 2017

Keywords provided by Merck KGaA, Darmstadt, Germany:
Assisted Reproductive Technology (ART)
Infertility
Ovarian stimulation

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Chorionic Gonadotropin
Follicle Stimulating Hormone
Reproductive Control Agents
Physiological Effects of Drugs
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists